GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NewAmsterdam Pharma
Shares of NewAmsterdam Pharma, a biotech company, are driven by hopes for its cholesterol-lowering drug. The price chart reflects the drug's potential to become a blockbuster in a huge market, but also the high risks associated with clinical trials.
Share prices of companies in the market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. We classify it in the pharmaceuticals (metabolism) sector, and the chart below reflects general trends and investor sentiment in this sector.
Broad Market Index - GURU.Markets
NewAmsterdam Pharma is a biopharmaceutical company developing drugs for the treatment of cardiometabolic diseases, particularly cholesterol-lowering drugs. Its focus on this issue makes it a prominent player in the GURU.Markets index. The chart below shows the entire market. Find out how NAMS compares to it.
Change in the price of a company, segment, and market as a whole per day
NAMS - Daily change in the company's share price NewAmsterdam Pharma
Shares of NewAmsterdam Pharma, a company developing cholesterol-lowering drugs, are highly volatile. Change_co reflects sensitivity to clinical trial news. This metric, while unspectacular in itself, is a critical component of the formulas on System.GURU.Markets that assess biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
NewAmsterdam Pharma Company N.V. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with NAMS's performance, which depends on clinical trial results, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
NewAmsterdam Pharma is a biopharmaceutical company developing drugs for the treatment of cardiovascular diseases. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with NAMS's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NewAmsterdam Pharma
NewAmsterdam is a biotech company specializing in the treatment of metabolic diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
NewAmsterdam Pharma is a late-stage biotech company developing drugs for the treatment of cardiovascular diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for a breakthrough in the treatment of one of the most common diseases.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NewAmsterdam Pharma is a late-stage biotech whose future hinges on the success of its cholesterol-lowering drug. Its stock price is completely disconnected from economic cycles. The chart reflects scientific events—news about clinical trials and regulatory decisions—rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NewAmsterdam Pharma
The performance of NewAmsterdam Pharma, a biopharmaceutical company, is speculative. The monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its cholesterol-lowering drug, the success of which determines its ability to compete in the vast cardiology market.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
NewAmsterdam Pharma is a biopharmaceutical company developing an oral drug to lower LDL cholesterol as an adjunct to statins. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess how the company's huge potential market and promising clinical data influence investor valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. Cardiovascular disease is a huge market. The chart below shows how disconnected the stock's performance was from the broader market, moving in sync with clinical trial news rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NewAmsterdam Pharma
Shares of NewAmsterdam Pharma, a biopharmaceutical company, move in sync with clinical trial news. Weekly price movements reflect investor expectations for their cardiovascular drug. The chart below illustrates how any news about trial progress can trigger sharp short-term fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
How does NewAmsterdam Pharma compare to the broader biotech sector? This chart compares the company's weekly share price movements with the overall trend. This helps us understand whether the stock price movement driven by the cardiovascular treatment news is the result of a unique event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NewAmsterdam Pharma develops cholesterol-lowering drugs. This chart compares its weekly performance with the market. It shows how much its stock, like other biotechs, depends on clinical trial results and the potential of its drug to become a blockbuster, rather than on general market trends.
Market capitalization of the company, segment and market as a whole
NAMS - Market capitalization of the company NewAmsterdam Pharma
NewAmsterdam Pharma's valuation reflects investors' hopes for its drug obecetrapib, designed to lower "bad" cholesterol. This biotech company's market cap depends entirely on the results of clinical trials. The chart vividly illustrates how the market reacts to every piece of news in this multi-billion-dollar race for the next blockbuster.
NAMS - Share of the company's market capitalization NewAmsterdam Pharma within the market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. Its share of its sector market capitalization reflects the huge potential market for its lead candidate. The chart shows how investor expectations for clinical trial results and potential success in the statin market shape its value.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total value of biotech companies tackling cardiovascular and metabolic diseases. NewAmsterdam Pharma is a prominent example of this segment. The chart's dynamics reflect the hopes associated with the discovery of new drugs to lower "bad" cholesterol.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart below shows the market valuation of a scientific breakthrough in the fight against cardiovascular disease. NewAmsterdam Pharma's market capitalization soared on expectations for its new cholesterol-lowering drug. The line illustrates how a single molecule can create enormous value and become a significant player in global healthcare.
Book value capitalization of the company, segment and market as a whole
NAMS - Book value capitalization of the company NewAmsterdam Pharma
The book value of clinical-stage NewAmsterdam Pharma is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for cholesterol-lowering drugs and its research reserves. The dynamics demonstrate how the company is investing in the development of its core asset.
NAMS - Share of the company's book capitalization NewAmsterdam Pharma within the market segment - Pharma metabolism
For NewAmsterdam Pharma, which is in clinical development, its tangible assets consist of laboratories and offices. The chart shows its modest share of the pharmaceutical sector's physical infrastructure, emphasizing that its primary value at this stage lies in its intellectual property and clinical trial data.
Market segment balance sheet capitalization - Pharma metabolism
NewAmsterdam Pharma is a late-stage biotech company. Its value is created in the labs where innovative drugs are developed. This is a "light" model based on intellectual capital. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
NewAmsterdam Pharma's balance sheet is capital focused on developing a single, promising cholesterol-lowering drug. The book value chart shows the financial resources concentrated on this potential blockbuster, targeting the vast cardiovascular market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NewAmsterdam Pharma
NewAmsterdam Pharma is a biotech company developing a drug to lower "bad" cholesterol. It has no revenue and almost no assets other than cash. Its entire market capitalization is based on the potential of its single drug to become a blockbuster. The graph is pure speculation based on the results of future clinical trials.
Market to book capitalization ratio in a market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. The company has no sales and minimal tangible assets. Its market capitalization is a bet on the success of its lead candidate's clinical trials. The chart reflects a high valuation of this potential.
Market to book capitalization ratio for the market as a whole
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. The chart shows how the market values this potential blockbuster cardiovascular treatment. Its market capitalization is a bet on the success of clinical trials and is unrelated to its small tangible assets, which is typical for biotech companies.
Debts of the company, segment and market as a whole
NAMS - Company debts NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biotech company focused on treating cardiovascular diseases. Debt instruments are a way for such companies to extend their financial runway, allowing them to complete key clinical trials before bringing their product to market.
Market segment debts - Pharma metabolism
NewAmsterdam Pharma is a biotech company in late-stage clinical trials developing cholesterol-lowering drugs. Bringing a new drug to market is a long and expensive process. This chart illustrates the financial norms in the pharmaceutical industry, which underpin the company's efforts to raise capital to complete trials and prepare for commercial launch.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NewAmsterdam Pharma
NewAmsterdam Pharma is a biotech company in the late-stage development of a cholesterol-lowering drug. Funding for late-stage clinical trials and preparation for market entry requires hundreds of millions of dollars. This chart shows how the company is using capital to advance its development.
Market segment debt to market segment book capitalization - Pharma metabolism
NewAmsterdam Pharma is a biotech company focused on treating metabolic diseases such as high cholesterol. This chart compares its debt raised to fund clinical trials to the overall market capitalization of the pharmaceutical sector. It demonstrates the scale of its efforts to combat common diseases.
Debt to book value of all companies in the market
NewAmsterdam Pharma is a biotech company targeting the mass market for metabolic disease treatments. This chart compares its debt, taken on for large-scale research, to the total book value of the entire economy. It shows how significant the company's financial stakes are in the success of its drug, relative to the overall stock market.
P/E of the company, segment and market as a whole
P/E - NewAmsterdam Pharma
This metric for NewAmsterdam Pharma, a biopharmaceutical company developing cholesterol-lowering drugs, reflects investor expectations. For a clinical-stage company, value is determined by the potential of its drugs to become blockbusters. The graph shows how much the market believes in the success of its developments and their ability to compete in a huge market.
P/E of the market segment - Pharma metabolism
This metric represents the average valuation for the biotech sector in which NewAmsterdam Pharma operates. In this industry, which is full of research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
NewAmsterdam Pharma is developing an innovative drug to lower "bad" cholesterol, targeting patients who are not achieving their goals with statins. The company operates in the vast cardiovascular market. This chart, reflecting risk appetite, helps understand how investors value biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biotech company developing a drug to lower LDL cholesterol. This chart reflects investor expectations regarding the success of clinical trials and the potential to capture the vast cardiovascular market. It's a bet on a scientific breakthrough in cardiology.
%20P%2FE%20NewAmsterdam%20Pharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NewAmsterdam-Pharma&v=1772513912294 "Chart of the company's future (projected) P/E NewAmsterdam Pharma")
Future (projected) P/E of the market segment - Pharma metabolism
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing oral medications for the treatment of cardiovascular diseases, specifically for lowering LDL cholesterol. This chart shows overall market sentiment toward the biotech sector, helping to assess NewAmsterdam's potential in its important therapeutic niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772513912343 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
NewAmsterdam Pharma is a biotech company developing a drug to lower "bad" cholesterol. It is a potential blockbuster for the vast cardiovascular market. The company's valuation is based on success in clinical trials, not on overall market forecasts.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513912348 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of cardiovascular and metabolic diseases. Its financial indicators currently reflect the costs of conducting clinical trials. This chart illustrates the investment required to bring a new drug to market targeting a large market.
Profit of companies in the market segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing cholesterol-lowering drugs for patients at high risk of cardiovascular disease. This chart shows the profitability of the company's metabolic pharmaceutical segment. The company's ongoing R&D expenditures impact overall profitability, but its success could offer new treatment options for millions of people and drive growth.
Overall market profit
NewAmsterdam Pharma is a biotech company developing drugs to treat cardiovascular and metabolic diseases. Its success is determined by clinical trial results and potential demand from the healthcare system. This chart illustrates general economic cycles, while NewAmsterdam is focused on solving global health problems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NewAmsterdam Pharma
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on drugs for the treatment of cardiovascular diseases related to metabolism. This chart reflects analysts' earnings expectations based on the potential of its lead candidate to become a blockbuster in the vast cholesterol-lowering drug market.
%20profit%20of%20the%20company%20NewAmsterdam%20Pharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NewAmsterdam-Pharma&v=1772513912460 "Graph of future (projected) profit of the company NewAmsterdam Pharma")
Future (predicted) profit of companies in the market segment - Pharma metabolism
NewAmsterdam Pharma is a biopharmaceutical company developing drugs for the treatment of cardiovascular and metabolic diseases, particularly cholesterol-lowering drugs. This chart shows profitability forecasts for the metabolic pharmaceutical segment. It reflects expectations for new treatments capable of satisfying the enormous market demand.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772513912494 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. Cardiovascular disease is a global problem, and the demand for effective treatments is enormous. The overall profit forecast shown here impacts the investment climate. This positive environment facilitates raising the capital needed to complete research and enter the market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513912519 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NewAmsterdam Pharma
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. It has no stable revenue at the clinical stage. P/S will be a key indicator after the product's launch. The chart will show how the market will evaluate initial sales, given the huge potential market for such drugs.
P/S market segment - Pharma metabolism
NewAmsterdam Pharma is a late-stage biotech company developing a drug to lower "bad" cholesterol. The potential market for such a drug is enormous. The chart reflects investors' high expectations for the future blockbuster, reflected in a high valuation relative to the currently unattainable commercial revenue.
P/S of the market as a whole
NewAmsterdam Pharma is a biotech company developing a drug to lower "bad" cholesterol. While revenue is currently unknown, its market cap reflects the enormous potential market for such a drug. This chart, based on actual revenue, clearly demonstrates that the company's valuation is betting on the success of a single key clinical trial.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NewAmsterdam Pharma
NewAmsterdam Pharma is a biotech company developing a drug to lower "bad" cholesterol. Its valuation depends on the success of this candidate. This chart shows investor expectations for future sales in the vast cardiovascular market if the drug is approved and becomes a viable therapy.
%20P%2FS%20NewAmsterdam%20Pharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NewAmsterdam-Pharma&v=1772513912674 "The graph of the company's future (projected) P/S NewAmsterdam Pharma")
Future (projected) P/S of the market segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing oral medications for the treatment of metabolic diseases, specifically those that lower LDL cholesterol. This chart shows how the market assesses the future commercial potential of its lead drug candidate compared to other companies in the cardiometabolic diseases sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772513912685 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
NewAmsterdam Pharma is developing cholesterol-lowering drugs, targeting the vast cardiovascular market. The company's success could benefit millions of patients. This chart shows revenue expectations for the entire market, and NAMS exemplifies how biotech companies targeting mass diseases are generating high growth expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513912689 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NewAmsterdam Pharma
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing drugs for the treatment of cardiovascular and metabolic diseases. Its revenue is likely absent or minimal in this chart, as the company does not yet have commercial products and its income may come from licensing fees.
Sales of companies in the market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company focused on treating cardiovascular and metabolic diseases. At this stage, its revenue, if any, is likely derived from partnerships. This chart allows investors to assess the financial support from pharma giants, which confirms the potential of its developments.
Overall market sales
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. The need for such medications is enormous and unaffected by economic cycles. This timeline is irrelevant for the company, whose potential success is determined by clinical trial results and the ability to offer effective treatment to millions of patients.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NewAmsterdam Pharma
NewAmsterdam Pharma is a biopharmaceutical company developing cholesterol-lowering drugs. Its revenue forecast is based on expectations of successful clinical trials and the potential to capture a share of the vast cardiovascular disease market. This chart shows whether analysts believe its therapy will be a future blockbuster.
%20sales%20of%20the%20company%20NewAmsterdam%20Pharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NewAmsterdam-Pharma&v=1772513912785 "Schedule of future (projected) sales of the company NewAmsterdam Pharma")
Future (projected) sales of companies in the market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. This chart shows projected revenue for the pharmaceutical segment related to metabolism. It helps assess the size of the cardiovascular disease market and the potential demand for the new, effective treatments the company is developing.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772513912788 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. Its success depends on clinical trial results and regulatory approval. However, the overall economic situation, reflected in the chart, influences the investment climate. Positive market expectations facilitate raising the capital needed to complete research and bring the product to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513912829 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NewAmsterdam Pharma
NewAmsterdam Pharma is a biopharmaceutical company developing cholesterol-lowering drugs. This graph depicts its progress through late-stage clinical trials. It shows the level of investment in research, and its future ability to generate revenue is entirely dependent on the approval and commercial success of its lead candidate.
Market segment marginality - Pharma metabolism
NewAmsterdam Pharma is a biotech company focused on developing drugs for the treatment of cardiovascular and metabolic diseases. This chart reflects the potential value of its lead candidate. High future profitability will confirm its effectiveness and potential to capture a significant share of this vast market.
Market marginality as a whole
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. It's targeting the vast cardiovascular market. This chart shows average profitability, but for NAMS, only one outcome matters: successful completion of clinical trials, which could turn the company into a pharmaceutical giant.
Employees in the company, segment and market as a whole
Number of employees in the company NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biotech company developing cholesterol-lowering drugs. Its small team consists of experts in cardiometabolic diseases. Growing its team will mean moving into late-stage trials and preparing for potential commercialization.
Share of the company's employees NewAmsterdam Pharma within the market segment - Pharma metabolism
NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing cholesterol-lowering therapies. This chart highlights its scientific focus. It shows the percentage of leading cardiologists and lipid metabolism researchers working on a new class of cardiovascular drugs within the company.
Number of employees in the market segment - Pharma metabolism
NewAmsterdam Pharma is a biopharmaceutical company developing cholesterol-lowering drugs. This chart illustrates employment in the metabolic research sector. The growing number of specialists in this field indicates high demand for new treatments for cardiovascular disease, which remains the leading cause of death worldwide.
Number of employees in the market as a whole
NewAmsterdam Pharma is a biotech company focused on developing drugs for the treatment of cardiovascular diseases. The growth of its scientific team is directly linked to progress in clinical trials. This is an example of how investments in healthcare create highly skilled jobs aimed at solving global health problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma is a late-stage biotech developing a cholesterol-lowering drug. Their enormous market capitalization is based on the potential of this single drug to become a blockbuster. This chart is a prime example of how the market values intellectual capital, where a breakthrough idea from a small team can be worth billions of dollars.
%20of%20the%20company%20NewAmsterdam%20Pharma%20(NAMS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NewAmsterdam-Pharma-NAMS&v=1772513913285 "Chart of market capitalization per employee (in thousands of dollars) of the company NewAmsterdam Pharma (NAMS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
NewAmsterdam Pharma is a late-stage biotech developing a cholesterol-lowering drug (obicetrapib). Its entire value lies in the potential of this single R&D product. This chart shows the industry average. It demonstrates the enormous (and speculative) market value investors are placing on the potential of this research team.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772513913397 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
NewAmsterdam Pharma is a biotech company developing cholesterol-lowering drugs. Its entire value is concentrated in the potential of one key drug. This chart reflects investor expectations: a high valuation per employee indicates confidence that a small scientific team can bring a blockbuster to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513913454 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma is a clinical-stage biotech company developing drugs to lower "bad" cholesterol (LDL). This represents a huge potential market. This negative-growth graph shows how much investment is spent on each employee conducting expensive clinical trials in hopes of creating the next blockbuster.
%20Chart%20NewAmsterdam%20Pharma%20(NAMS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NewAmsterdam-Pharma-NAMS&v=1772513913506 "Company Profit Per Employee (in thousands of dollars) Chart NewAmsterdam Pharma (NAMS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biotech company developing a cholesterol-lowering drug (Obicetrapib). This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through money on R&D (clinical trials).
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772513913554 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
NewAmsterdam Pharma is a biotech company developing drugs to treat metabolic diseases, specifically to lower "bad" cholesterol. This R&D focus spans a very broad area. This metric, which illustrates the average profitability per employee in the economy, helps understand how this R&D sector compares to the average profitability of its workforce.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513913591 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma, a biotech company in late-stage clinical trials, currently has no significant sales. This chart illustrates its scientific potential. If the new drug is approved and successfully launched, revenue per employee should skyrocket, reflecting the commercial value of its innovations.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NewAmsterdam-Pharma-NAMS&v=1772513913609 "Sales chart per company employee NewAmsterdam Pharma (NAMS)")
Sales per employee in the market segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biotech company focused on metabolic diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of NAMS staff in the industry.
Sales per employee for the market as a whole
NewAmsterdam Pharma (NAMS) is a late-stage biotech developing cholesterol-lowering drugs. Like other biotechs (CGON, MLYS), the company is in the phase of high R&D and pre-launch preparation. This metric does not yet reflect efficacy. Investors are awaiting approval, which should lead to a sharp rise in the company's price.
Short shares by company, segment and market as a whole
Shares shorted by company NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma is a biotech company developing a drug (obicetrapib) to lower "bad" cholesterol (LDL). It's a huge but extremely competitive market. This chart shows that the bears don't believe in their success. They're betting the drug won't be able to compete with existing blockbusters from pharmaceutical giants.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NewAmsterdam-Pharma-NAMS&v=1772513913730 "Short Shares Chart for the Company NewAmsterdam Pharma (NAMS)")
Shares shorted by market segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biotech company developing drugs to lower "bad" cholesterol. This chart shows pessimism in the pharmaceutical sector. The increase in short positions in the industry may reflect concerns about intense competition in the cardiovascular drug market, already dominated by giants and cheap generics.
Shares shorted by the overall market
New Amsterdam Pharma (NAMS) is a clinical-stage biotech developing cholesterol-lowering drugs. This represents a huge potential market. This chart measures overall market pessimism. When investors are fearful, they sell off speculative biotechs that lack revenue. NAMS shares may fall along with the market due to the overall risk-off sentiment, not the science.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma is a clinical-stage biotech company focused on cardiovascular diseases. The stock is sensitive to R&D news. This chart can surge above 70 on positive trial data. Oversold territory (<30) often reflects setbacks or concerns about funding or competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NewAmsterdam-Pharma-NAMS&v=1772513913810 "RSI 14 indicator chart for the company's stock NewAmsterdam Pharma (NAMS)")
RSI 14 Market Segment - Pharma metabolism
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases, specifically those that lower LDL cholesterol. This chart shows the overall sentiment in the metabolism-focused biotech sector. It helps distinguish the NAMS trend from the broader trend driven, for example, by the hype around weight-loss drugs.
RSI 14 for the overall market
NewAmsterdam Pharma (NAMS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NAMS (NewAmsterdam Pharma)
NewAmsterdam Pharma is a biotech company developing drugs to treat metabolic diseases, primarily to lower "bad" cholesterol. This chart shows the average analyst forecast. Their targets are based on the potential of the lead drug (obicetrapib) as an adjunct to statins and its chances of success in trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NAMS-NewAmsterdam-Pharma&v=1772513913860 "A chart showing analyst consensus forecasts for the expected stock price. NAMS (NewAmsterdam Pharma)")
The difference between the consensus estimate and the actual stock price NAMS (NewAmsterdam Pharma)
NewAmsterdam Pharma is a clinical-stage biotech company developing a drug (Obicetrapib) to lower bad cholesterol (LDL). Their goal is to create a convenient pill as a complement to statins. This chart reflects analysts' expectations for their clinical data in this huge market. It shows the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NAMS-NewAmsterdam-Pharma&v=1772513913884 "A chart showing the difference between the consensus forecast and the actual stock price. NAMS (NewAmsterdam Pharma)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
NewAmsterdam Pharma is a biotech company targeting a huge market: lowering "bad" cholesterol (LDL) for patients who don't respond to statins. This chart shows analysts' overall expectations for the "metabolism" sector. It reflects whether experts believe there will be breakthroughs in new cardiovascular treatments.
Analysts' consensus forecast for the overall market share price
NewAmsterdam Pharma (NAMS) is a biotech company developing drugs to treat metabolic diseases. Their lead candidate is aimed at lowering bad cholesterol in high-risk patients. This chart shows the overall risk appetite, reflecting the market's willingness to fund research in such high-volume yet competitive fields.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NewAmsterdam Pharma
NewAmsterdam Pharma is a late-stage biotech company focused on a single goal: developing a drug (obicetrapib) to lower bad cholesterol (LDL). This chart represents pure R&D investment. It likely reflects investors' faith in successful clinical trials and the enormous market potential of their drug, rather than revenue.
AKIMA Market Segment Index - Pharma metabolism
New Amsterdam Pharma (NAMS) is a clinical-stage biotech focused on metabolic diseases; the company is developing an oral (tablet) cholesterol-lowering drug (Obicetrapib) (an alternative to statins). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does NAMS's large (cholesterol) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
New Amsterdam (NAMS) is a clinical-stage biotech company focused on cardiovascular disease, specifically cholesterol reduction. This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop for funding such companies.
